Stroke is the second most common cause of death and the third most common cause of disability worldwide.[@b1],[@b2] As stroke mortality has decreased over the past 2 decades, the absolute number of stroke survivors has increased and is huge.[@b3] Given the high recurrence rate, secondary prevention of future stroke among these survivors plays a pivotal role in reducing disease burden.[@b4] The use of antiplatelet agents is the standard treatment for patients with noncardioembolic ischemic stroke or transient ischemic attack (TIA).[@b4] A number of randomized controlled trials (RCTs) have tested different antiplatelet mono- and dual therapies in secondary prevention after ischemic stroke or TIA[@b5]--[@b28]; however, comparisons of some antiplatelet therapies are currently lacking.

Several pairwise meta-analyses were performed previously to compare the efficacy of antiplatelet agents for the secondary prevention of stroke.[@b29]--[@b31] These studies, however, could not generate clear hierarchies for the efficacy and safety of all available antiplatelet therapies because many antiplatelet treatments have not been compared head to head and because such analyses could not integrate all of the evidence from several comparators. Using a statistical technique called *network meta-analysis*, we were able to take advantage of both direct (head-to-head) and indirect evidence and formally compare all existing therapies.[@b32],[@b33]

Two previous network meta-analyses were conducted to compare the efficacy of antiplatelet therapies among stroke or TIA patients[@b34],[@b35]; however, neither provided hierarchies for the efficacy and safety of antiplatelet therapies. The earlier study compared only a small number of antiplatelet therapies.[@b34] The later study identified 24 trials published before March 2012[@b35] but failed to incorporate a few major large-scale trials, such as the SPS3 trial,[@b24] the JASAP study,[@b17] and the study published by Fukuuchi et al.[@b14] In addition, the second network meta-analysis did not restrict the duration of antiplatelet therapy.[@b35] Because the American Heart Association/American Stroke Association (AHA/ASA) guidelines recommend that patients with ischemic stroke or TIA continuously receive antiplatelet treatment,[@b4] we believe it is more important to evaluate overall recurrent stroke reduction and bleeding risk of long-term antiplatelet therapies in these patients. To achieve this goal, we performed the network meta-analysis of RCTs to compare the effectiveness and safety of long-term antiplatelet treatments among patients with ischemic stroke or TIA.

Methods
=======

This study was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement.[@b36] Ethics approval was not necessary for this study because only deidentified pooled data from individual studies were analyzed.

Data Sources and Search Strategy
--------------------------------

A systematic literature search was conducted December 26, 2014, by searching Medline via Web of Science, Embase and Journals\@Ovid Full Text via OvidSP, and the Cochrane Library database for trials. We limited our search to RCTs conducted in humans. Details of our search strategy are provided in [Table S1](#sd1){ref-type="supplementary-material"}. The search strategy in the current study was similar to those used in previous studies.[@b37],[@b38]

Study Selection
---------------

RCTs were eligible for inclusion if they met the following criteria: Antiplatelet monotherapy versus monotherapy or dual versus monotherapy was tested in adult patients (aged ≥18 years) with ischemic stroke or TIA and had a treatment duration of at least 1 year. Because network meta-analysis requires a reasonably homogeneous sample,[@b39],[@b40] we did not include those RCTs assessing antiplatelet therapy (mostly aspirin) versus placebo because such studies had a wide range of daily doses (aspirin, from 75 to 1500 mg).[@b41],[@b42] Another reason is that the evaluation of antiplatelet therapy versus placebo becomes less important.

Initially, titles alone were reviewed for suitability. The abstracts of suitable titles were obtained and reviewed for suitability for full-text retrieval. Data were then extracted from suitable full-text reports. Additional appropriate reports were added when discovered by citation tracking.

Data Extraction and Quality Assessment
--------------------------------------

Data were independently extracted and assessed by 2 authors (F.Z. and B.Z.) using a predetermined data collection template. To resolve discrepancies about inclusion of studies and interpretation of data, a third investigator (W.X.) was consulted, and consensus was reached by discussion.

The primary efficacy outcome was stroke recurrence, including ischemic, hemorrhagic, and unknown stroke, and fatal and nonfatal stroke. The secondary efficacy outcome was the composite outcome of vascular events and all-cause or vascular mortality. The safety outcomes were intracranial hemorrhage and major bleeding. The definitions of the 4 outcomes in included trials are summarized in [Table S2](#sd1){ref-type="supplementary-material"}.

Study quality was independently assessed by 3 reviewers (F.Z., B.Z., and X.S.) who used the Cochrane Collaboration's risk-of-bias method.[@b43] [Figure S1](#sd1){ref-type="supplementary-material"} shows the risk of bias of the included trials.

Data Synthesis and Analysis
---------------------------

Network meta-analysis combines direct and indirect evidence for all relative treatment effects and provides estimates with maximum statistical power.[@b44]--[@b47] We fit the models within a Bayesian framework using WinBUGS software (version 1.4.3).[@b48] The models, the WinBUGS codes, and R routines used in this study were open and could be found online.[@b49] Convergence was assessed by running 3 Markov chains, and all results pertain to 100 000 Markov chain Monte Carlo cycles after a 10 000-simulation burn-in phase. Relative effect sizes were calculated as odds ratios (ORs) with corresponding 95% credible intervals. We assessed the fitness of our model using the deviance information criterion, a measure of model fitness that penalizes model complexity. If the tradeoff between model fitness and complexity favored the model with assumed consistency, this model was preferred (smaller deviance information criterion values correspond to more preferable values).[@b50] As shown in [Table S3](#sd1){ref-type="supplementary-material"}, the assumption of consistency was supported for each outcome by a better tradeoff between model fitness and complexity (a smaller deviance information criterion value) when consistency was assumed rather than when it was not. We used the surface under the cumulative ranking curve, or SUCRA, probabilities to rank the antiplatelet therapies:[@b47],[@b51] SUCRA is a proportion expressed as the percentage of efficacy of an intervention on the outcome that would be ranked first without uncertainty, which equals 100% when the treatment is certain to be the best and 0% when it is certain to be the worst.[@b47] The network results were assessed for consistency by comparing them with the results of pairwise meta-analyses. Furthermore, we estimated inconsistency as the difference between direct and indirect estimates (called the *inconsistency factor*) and the corresponding 95% confidence interval (CI) for inconsistency factor in each closed loop by using the R code *ifplot.fun*, which could be found online.[@b52] Inconsistent loops are those that present inconsistency factors with 95% CIs incompatible with zero. Pairwise meta-analyses were performed by using STATA (version 11; Stata Corp) within a random-effects framework that takes study heterogeneity into account to generate the pooled OR and 95% CI. The percentage of variability across studies attributable to heterogeneity beyond chance was estimated using the I^2^ statistic.

We did sensitivity analyses on the primary efficacy outcome to explore whether the results of the present network meta-analysis were sensitive to certain restrictions on the data included. Those planned in advance were restricted to double-blind trials (n=18) and true randomization and allocation-concealed trials (n=16).

Results
=======

Study Selection and Characteristics
-----------------------------------

[Figure 1](#fig01){ref-type="fig"} shows the study selection process according to the PRISMA statement. The initial search and citation tracking identified 2678 publications. Fifty-five articles were reviewed by full text for details, and 31 of those were excluded. Finally, a total of 24 RCTs with 85 667 patients were included in the present network meta-analysis.[@b5]--[@b28] [Tables 1](#tbl1){ref-type="table"} and [2](#tbl2){ref-type="table"} summarize the characteristics of the 24 included trials. The following antiplatelet therapies were tested in the trials: cilostazol versus aspirin (3 trials with 3459 patients),[@b9],[@b11],[@b15] clopidogrel versus aspirin (1 trial with 6431 patients),[@b8] dipyridamole versus aspirin (1 trial with 3303 patients),[@b13] sarpogrelate versus aspirin (1 trial with 1499 patients),[@b23] terutroban versus aspirin (1 trial with 19 100 patients),[@b21] ticlopidine versus aspirin (4 trials with 5488 patients),[@b5],[@b16],[@b18],[@b27] ticlopidine versus clopidogrel (1 trial with 1151 patients),[@b14] triflusal versus aspirin (2 trials with 2536 patients),[@b25],[@b26] aspirin plus clopidogrel versus aspirin (2 trials with 7340 patients),[@b10],[@b24] aspirin plus clopidogrel versus clopidogrel (1 trial with 7599 patients),[@b19] aspirin plus dipyridamole versus aspirin (5 trials with 8622 patients),[@b6],[@b7],[@b12],[@b13],[@b17] aspirin plus dipyridamole versus clopidogrel (1 trial with 20 332 patients),[@b22] aspirin plus dipyridamole versus dipyridamole (2 trials with 3490 patients),[@b13],[@b20] and aspirin plus ticlopidine versus ticlopidine (1 trial with 270 patients).[@b28]

![Study selection flow diagram adapted from the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. IS indicates ischemic stroke; TIA, transient ischemic attack.](jah30004-e002259-f1){#fig01}

###### 

Baseline Characteristics of Included Trials

  Trial                    Country              Centers   Patients        Sample Size   Treatment Onset, Month   Treatment Duration, Month   Male, %   Mean Age, Y   Follow-Up, Mo   Lost to Follow-Up, %   Blinding
  ------------------------ -------------------- --------- --------------- ------------- ------------------------ --------------------------- --------- ------------- --------------- ---------------------- ---------------------------------
  AAASPS 2003[@b5]         US                   62        IS              1809          0.25 to 3                19 (mean)                   47        61            19 (mean)       3.8                    Double-blind
  ACCSG 1985[@b6]          US and Canada        15        TIA             890           \<3                      18 (median)                 67        63            25 (median)     4.2                    Double-blind
  AICLA 1983[@b7]          France               4         IS, TIA         400           \<12                     36                          69        63            36              3.8                    Double-blind
  CAPRIE 1996[@b8]         Worldwide            384       IS              6431          0.25 to 6                20 (mean)                   64        65            23 (mean)       0.7                    Double-blind
  CASISP 2008[@b9]         China                13        IS              719           1 to 6                   12 to 18                    69        60            12 (mean)       1.3                    Double-blind
  CHARISMA 2011[@b10]      Worldwide            768       IS, TIA         4320          \<60                     25 (median)                 63        65            25 (median)     0.5                    Double-blind
  CSPS2 2010[@b11]         Japan                278       IS              2672          \<7                      12 to 60                    72        64            29 (mean)       0.2                    Double-blind
  ESPRIT 2006[@b12]        Worldwide            79        Minor IS, TIA   2739          \<6                      42 (mean)                   66        63            42 (mean)       3.8                    Open
  ESPS2 1996[@b13]         Europe               59        IS, TIA         4953          \<3                      24                          58        67            24              0.6                    Double-blind
  Fukuuchi 2007[@b14]      Japan                129       IS              1151          \>0.25                   52                          73        65            52              NS                     Double-blind
  Guo 2009[@b15]           China                1         IS              68            1 to 6                   12                          35        61            12              NS                     NS
  Hass 1989[@b16]          US and Canada        56        IS, TIA, RI     3069          \<3                      27 (mean)                   65        63            24 to 72        2.7                    Double-blind
  JASAP 2011[@b17]         Japan                157       IS              1294          0.25 to 6                15 (mean)                   72        66            24              0.2                    Double-blind
  Li 2000[@b18]            China                9         IS, TIA         329           NS                       12 (mean)                   71        64            12 (mean)       2.4                    NS
  MATCH 2004[@b19]         Worldwide            507       IS, TIA         7599          \<3                      18                          63        66            18              4.3                    Double-blind
  Matias-Guiu 1987[@b20]   Spain                1         TIA             186           \<12                     21 (mean)                   77        55            21 (mean)       4.5                    Open
  PERFORM 2011[@b21]       Worldwide            802       IS, TIA         19 100        \<3                      28 (mean)                   63        67            28 (mean)       0.3                    Double-blind
  PRoFESS 2008[@b22]       Worldwide            695       IS              20 332        \<3                      30 (mean)                   64        66            30 (mean)       0.6                    Double-blind
  S-ACCESS 2008[@b23]      Japan                14        IS              1499          0.25 to 6                19 (mean)                   72        65            19 (mean)       NS                     Double-blind
  SPS3 2012[@b24]          Worldwide            82        IS              3020          \<6                      41 (mean)                   63        63            41 (mean)       2.0                    Double-blind
  TACIP 2003[@b25]         Portugal and Spain   43        IS, TIA         2107          \<6                      12 to 36                    66        65            30 (mean)       2.1                    Double-blind
  TAPIRSS 2004[@b26]       Argentina            19        IS, TIA         429           \<6                      19 (mean)                   68        65            19 (mean)       NS                     Double-blind
  Tohgi 1987[@b27]         Japan                101       TIA             281           \<3                      36                          NS        NS            36              NS                     12-mo double-blind, ≥24-mo open
  TOPALS 2003[@b28]        Japan                25        IS, TIA         270           \<6                      19 (mean)                   65        67            19 (mean)       NS                     NS

IS indicates ischemic stroke; NS, not specified; RI, retinal ischemia; TIA, transient ischemic attack.

###### 

Antiplatelet Treatments and Outcomes of Included Trials

  Trial                    Treatment Groups and Dosages             Stroke Recurrence       Composite Outcome   Intracranial Hemorrhage   Major Bleeding                                                                                                               
  ------------------------ ---------------------------------------- ----------------------- ------------------- ------------------------- ---------------- ---------- ------------- ------------- ---------- ------------ ------------ ----- ------------ ------------ ---------
  AAASPS 2003[@b5]         Tic (250 mg BID)                         Asp (325 mg BID)        ---                 107/902                   86/907           ---        145/902       125/907       ---        NS           NS           ---   4/902        8/907        ---
  ACCSG 1985[@b6]          Asp (325 mg QID)+Dip (75 mg QID)         Asp (325 mg QID)        ---                 53/448                    60/442           ---        99/448        96/442        ---        2/448        4/442        ---   15/448       21/442       ---
  AICLA 1983[@b7]          Asp (330 mg TID)+Dip (75 mg TID)         Asp (330 mg TID)        ---                 18/202                    17/198           ---        28/202        30/198        ---        1/202        2/198        ---   3/202        3/198        ---
  CAPRIE 1996[@b8]         Clop (75 mg OD)                          Asp (325 mg OD)         ---                 315/3233                  338/3198         ---        433/3233      461/3198      ---        NS           NS           ---   NS           NS           ---
  CASISP 2008[@b9]         Cilo (100 mg BID)                        Asp (100 mg OD)         ---                 12/360                    20/359           ---        24/360        37/359        ---        1/360        5/359        ---   1/360        6/359        ---
  CHARISMA 2011[@b10]      Asp (75 to 162 mg OD)+Clop (75 mg OD)    Asp (75 to 162 mg OD)   ---                 105/2157                  131/2163         ---        174/2157      207/2163      ---        13/2157      11/2163      ---   92/2157      61/2163      ---
  CSPS2 2010[@b11]         Cilo (100 mg BID)                        Asp (81 mg OD)          ---                 82/1337                   119/1335         ---        138/1337      186/1335      ---        8/1337       27/1335      ---   23/1337      57/1335      ---
  ESPRIT 2006[@b12]        Asp (30 to 325 mg OD)+Dip (200 mg BID)   Asp (30 to 325 mg OD)   ---                 108/1363                  137/1376         ---        198/1363      239/1376      ---        12/1363      21/1376      ---   35/1363      53/1376      ---
  ESPS2 1996[@b13]         Asp (25 mg BID)+Dip (200 mg BID)         Dip (200 mg BID)        Asp (25 mg bid)     157/1650                  211/1654         206/1649   206/1650      271/1654      266/1649   NS           NS           NS    60/1650      24/1654      53/1649
  Fukuuchi 2007[@b14]      Clop (75 mg OD)                          Tic (200 mg OD)         ---                 17/573                    15/578           ---        25/573        24/578        ---        4/573        1/578        ---   5/573        1/578        ---
  Guo 2009[@b15]           Cilo (100 mg BID)                        Asp (100 mg OD)         ---                 2/34                      2/34             ---        2/34          5/34          ---        0/34         1/34         ---   0/34         2/34         ---
  Hass 1989[@b16]          Tic (250 mg BID)                         Asp (650 mg BID)        ---                 172/1529                  212/1540         ---        306/1529      349/1540      ---        7/1529       7/1540       ---   14/1529      28/1540      ---
  JASAP 2011[@b17]         Asp (25 mg BID)+Dip (200 mg BID)         Asp (81 mg OD)          ---                 57/655                    39/639           ---        69/655        58/639        ---        13/655       13/639       ---   26/655       23/639       ---
  Li 2000[@b18]            Tic (250 mg OD)                          Asp (50 mg OD)          ---                 11/165                    21/164           ---        13/165        26/164        ---        6/165        4/164        ---   7/165        7/164        ---
  MATCH 2004[@b19]         Asp (75 mg OD)+Clop (75 mg OD)           Clop (75 mg OD)         ---                 339/3797                  347/3802         ---        552/3797      567/3802      ---        40/3759      25/3781      ---   73/3759      22/3781      ---
  Matias-Guiu 1987[@b20]   Asp (50 mg OD)+Dip (100 mg TID)          Dip (100 mg QID)        ---                 9/115                     7/71             ---        25/115        15/71         ---        NS           NS           ---   NS           NS           ---
  PERFORM 2011[@b21]       Teru (30 mg OD)                          Asp (100 mg OD)         ---                 842/9556                  828/9544         ---        1530/9556     1485/9544     ---        146/9479     121/9466     ---   211/9479     210/9466     ---
  PRoFESS 2008[@b22]       Asp (25 mg BID)+Dip (200 mg BID)         Clop (75 mg OD)         ---                 916/10 181                898/10 151       ---        1637/10 181   1630/10 151   ---        147/10 181   103/10 151   ---   419/10 181   365/10 151   ---
  S-ACCESS 2008[@b23]      Sarp (100 mg TID)                        Asp (81 mg OD)          ---                 79/747                    70/752           ---        110/747       98/752        ---        9/750        12/757       ---   NS           NS           ---
  SPS3 2012[@b24]          Asp (325 mg OD)+Clop (75 mg OD)          Asp (325 mg OD)         ---                 125/1517                  138/1503         ---        239/1517      232/1503      ---        22/1517      15/1503      ---   105/1517     56/1503      ---
  TACIP 2003[@b25]         Trif (600 mg OD)                         Asp (325 mg OD)         ---                 109/1055                  112/1052         ---        145/1055      141/1052      ---        7/1055       11/1052      ---   20/1055      42/1052      ---
  TAPIRSS 2004[@b26]       Trif (600 mg OD)                         Asp (325 mg OD)         ---                 18/213                    18/216           ---        27/213        34/216        ---        1/214        2/216        ---   1/214        7/216        ---
  Tohgi 1987[@b27]         Tic (200 mg OD)                          Asp (500 mg BID)        ---                 4/136                     8/145            ---        29/136        46/145        ---        2/136        2/145        ---   NS           NS           ---
  TOPALS 2003[@b28]        Asp (81 mg OD)+Tic (100 mg OD)           Tic (200 mg OD)         ---                 9/132                     7/138            ---        13/132        14/138        ---        2/132        0/138        ---   NS           NS           ---

Asp indicates aspirin; Cilo, cilostazol; Clop, clopidogrel; Dip, dipyridamole; NS, not specified; Sarp, sarpogrelate; Teru, terutroban; Tic, ticlopidine; Trif, triflusal.

Network Meta-Analysis
---------------------

The network of antiplatelet treatment comparisons for stroke recurrence is shown in [Figure 2](#fig02){ref-type="fig"}. The network meta-analysis results for stroke recurrence and intracranial hemorrhage are reported in [Table 3](#tbl3){ref-type="table"}. Cilostazol significantly reduced stroke recurrence compared with aspirin (OR 0.66, 95% credible interval 0.44 to 0.92) and dipyridamole (OR 0.57, 95% credible interval 0.34 to 0.95), respectively. Intracranial hemorrhage was also significantly reduced by cilostazol compared with aspirin, clopidogrel, terutroban, ticlopidine, aspirin plus clopidogrel, and aspirin plus dipyridamole.

![Network of treatment comparisons for the primary efficacy outcome. The size of the node corresponds to the total sample size of the treatment from all included trials. Directly comparable treatments are linked with a line, the thickness of which corresponds to the total sample size for assessing the comparison.](jah30004-e002259-f2){#fig02}

###### 

Results for Stroke Recurrence (Upper Diagonal Part) and Intracranial Hemorrhage (Lower Diagonal Part) From Network Meta-Analyses

  Treatment   Asp                                                    Cilo                                                    Clop                  Dip                                                    Sarp                  Teru                  Tic                   Trif                  Asp+Clop              Asp+Dip               Asp+Tic
  ----------- ------------------------------------------------------ ------------------------------------------------------- --------------------- ------------------------------------------------------ --------------------- --------------------- --------------------- --------------------- --------------------- --------------------- ---------------------
  Asp         1.00                                                   0.66 (0.44 to 0.92)[\*](#tf3-2){ref-type="table-fn"}    0.89 (0.72 to 1.14)   1.13 (0.80 to 1.54)                                    1.19 (0.69 to 1.87)   1.04 (0.72 to 1.44)   0.87 (0.65 to 1.10)   0.98 (0.68 to 1.37)   0.85 (0.68 to 1.09)   0.89 (0.74 to 1.06)   1.45 (0.40 to 3.78)
  Cilo        0.27 (0.08 to 0.58)[\*](#tf3-2){ref-type="table-fn"}   1.00                                                    1.39 (0.91 to 2.16)   1.77 (1.06 to 2.94)[\*](#tf3-2){ref-type="table-fn"}   1.85 (0.97 to 3.12)   1.62 (0.98 to 2.64)   1.36 (0.85 to 2.15)   1.53 (0.90 to 2.47)   1.33 (0.86 to 2.05)   1.38 (0.91 to 2.13)   2.27 (0.59 to 6.48)
  Clop        0.74 (0.37 to 1.49)                                    3.62 (1.07 to 10.60)[\*](#tf3-2){ref-type="table-fn"}   1.00                  1.28 (0.85 to 1.79)                                    1.35 (0.75 to 2.15)   1.18 (0.75 to 1.73)   0.99 (0.70 to 1.32)   1.12 (0.70 to 1.65)   0.97 (0.74 to 1.23)   1.01 (0.77 to 1.27)   1.65 (0.43 to 4.39)
  Dip         ---                                                    ---                                                     ---                   1.00                                                   1.07 (0.59 to 1.80)   0.94 (0.58 to 1.50)   0.79 (0.50 to 1.16)   0.89 (0.52 to 1.41)   0.77 (0.52 to 1.12)   0.80 (0.58 to 1.12)   1.32 (0.33 to 3.56)
  Sarp        0.88 (0.23 to 2.32)                                    4.44 (0.78 to 14.55)                                    1.32 (0.27 to 3.90)   ---                                                    1.00                  0.93 (0.49 to 1.64)   0.78 (0.43 to 1.28)   0.88 (0.46 to 1.50)   0.76 (0.42 to 1.29)   0.79 (0.44 to 1.27)   1.30 (0.31 to 3.68)
  Teru        1.27 (0.53 to 2.45)                                    6.15 (1.55 to 16.85)[\*](#tf3-2){ref-type="table-fn"}   1.94 (0.56 to 4.37)   ---                                                    2.06 (0.41 to 6.21)   1.00                  0.87 (0.53 to 1.28)   0.98 (0.57 to 1.57)   0.85 (0.56 to 1.24)   0.88 (0.59 to 1.31)   1.44 (0.35 to 3.83)
  Tic         0.96 (0.39 to 2.02)                                    4.71 (1.09 to 14.72)[\*](#tf3-2){ref-type="table-fn"}   1.43 (0.46 to 3.34)   ---                                                    1.60 (0.31 to 5.17)   0.87 (0.28 to 2.19)   1.00                  1.14 (0.75 to 1.75)   0.99 (0.71 to 1.37)   1.03 (0.75 to 1.43)   1.67 (0.47 to 4.38)
  Trif        0.68 (0.18 to 1.72)                                    3.23 (0.59 to 10.75)                                    1.02 (0.20 to 2.89)   ---                                                    1.09 (0.15 to 3.94)   0.65 (0.13 to 1.67)   0.83 (0.16 to 2.62)   1.00                  0.90 (0.56 to 1.35)   0.93 (0.63 to 1.34)   1.53 (0.37 to 3.93)
  Asp+Clop    1.31 (0.67 to 2.46)                                    6.45 (1.72 to 19.79)[\*](#tf3-2){ref-type="table-fn"}   1.91 (0.94 to 3.50)   ---                                                    2.11 (0.48 to 6.08)   1.18 (0.42 to 2.87)   1.63 (0.52 to 3.90)   2.72 (0.66 to 7.90)   1.00                  1.05 (0.78 to 1.40)   1.73 (0.45 to 4.73)
  Asp+Dip     0.85 (0.46 to 1.37)                                    4.17 (1.20 to 11.06)[\*](#tf3-2){ref-type="table-fn"}   1.25 (0.55 to 2.03)   ---                                                    1.38 (0.32 to 3.81)   0.77 (0.26 to 1.78)   1.05 (0.34 to 2.30)   1.74 (0.42 to 5.12)   0.70 (0.29 to 1.32)   1.00                  1.65 (0.45 to 4.21)
  Asp+Tic     ---                                                    ---                                                     ---                   ---                                                    ---                   ---                   ---                   ---                   ---                   ---                   1.00

Each cell gives an odds ratio (OR) and 95% credible interval. In the upper diagonal part, the OR compares the column condition with the row condition, and in the lower diagonal part, this OR compares the row condition with the column condition. Asp indicates aspirin; Cilo, cilostazol; Clop, clopidogrel; Dip, dipyridamole; NS, not specified; Sarp, sarpogrelate; Teru, terutroban; Tic, ticlopidine; Trif, triflusal.

Significant results.

Similarly, cilostazol significantly reduced the composite outcome compared with aspirin (OR 0.68, 95% credible interval 0.48 to 0.93) and dipyridamole (OR 0.59, 95% credible interval 0.39 to 0.95) and reduced major bleeding compared with aspirin, clopidogrel, terutroban, aspirin plus clopidogrel, and aspirin plus dipyridamole ([Table 4](#tbl4){ref-type="table"}). In addition, dipyridamole, ticlopidine, and triflusal caused significantly less major bleeding than aspirin; terutroban caused significantly more major bleeding than dipyridamole and triflusal; aspirin plus clopidogrel caused significantly more major bleeding than aspirin, clopidogrel, dipyridamole, ticlopidine, triflusal, and aspirin plus dipyridamole; and aspirin plus dipyridamole caused significantly more major bleeding than dipyridamole and triflusal.

###### 

Results for Composite Outcome (Upper Diagonal Part) and Major Bleeding (Lower Diagonal Part), From Network Meta-Analyses

  Treatment   Asp                                                    Cilo                                                    Clop                                                   Dip                                                     Sarp                  Teru                                                   Tic                                                    Trif                                                    Asp+Clop                                               Asp+Dip               Asp+Tic
  ----------- ------------------------------------------------------ ------------------------------------------------------- ------------------------------------------------------ ------------------------------------------------------- --------------------- ------------------------------------------------------ ------------------------------------------------------ ------------------------------------------------------- ------------------------------------------------------ --------------------- ---------------------
  Asp         1.00                                                   0.68 (0.48 to 0.93)[\*](#tf4-2){ref-type="table-fn"}    0.93 (0.77 to 1.16)                                    1.11 (0.78 to 1.51)                                     1.17 (0.72 to 1.77)   1.04 (0.73 to 1.43)                                    0.86 (0.67 to 1.06)                                    0.96 (0.64 to 1.33)                                     0.92 (0.73 to 1.18)                                    0.88 (0.74 to 1.10)   0.93 (0.33 to 2.15)
  Cilo        0.35 (0.15 to 0.62)[\*](#tf4-2){ref-type="table-fn"}   1.00                                                    1.42 (0.95 to 2.10)                                    1.68 (1.06 to 2.54)[\*](#tf4-2){ref-type="table-fn"}    1.79 (0.98 to 2.95)   1.59 (0.95 to 2.48)                                    1.32 (0.85 to 1.92)                                    1.47 (0.86 to 2.33)                                     1.40 (0.91 to 2.06)                                    1.41 (0.97 to 2.04)   1.43 (0.48 to 3.49)
  Clop        0.74 (0.43 to 1.15)                                    2.50 (1.02 to 5.85)[\*](#tf4-2){ref-type="table-fn"}    1.00                                                   1.20 (0.79 to 1.72)                                     1.27 (0.75 to 2.05)   1.13 (0.75 to 1.56)                                    0.93 (0.67 to 1.20)                                    1.04 (0.65 to 1.57)                                     0.99 (0.75 to 1.30)                                    1.00 (0.78 to 1.28)   1.01 (0.35 to 2.34)
  Dip         0.40 (0.19 to 0.74)[\*](#tf4-2){ref-type="table-fn"}   1.30 (0.46 to 3.10)                                     0.57 (0.24 to 1.12)                                    1.00                                                    1.09 (0.56 to 1.79)   0.97 (0.57 to 1.56)                                    0.80 (0.52 to 1.17)                                    0.89 (0.53 to 1.37)                                     0.86 (0.57 to 1.29)                                    0.86 (0.62 to 1.17)   0.87 (0.28 to 2.02)
  Sarp        ---                                                    ---                                                     ---                                                    ---                                                     1.00                  0.94 (0.50 to 1.57)                                    0.78 (0.44 to 1.22)                                    0.87 (0.46 to 1.54)                                     0.83 (0.49 to 1.34)                                    0.83 (0.51 to 1.34)   0.84 (0.26 to 2.06)
  Teru        1.04 (0.56 to 1.76)                                    3.35 (1.35 to 7.55)[\*](#tf4-2){ref-type="table-fn"}    1.48 (0.66 to 2.90)                                    2.89 (1.12 to 6.04)[\*](#tf4-2){ref-type="table-fn"}    ---                   1.00                                                   0.85 (0.56 to 1.27)                                    0.95 (0.56 to 1.49)                                     0.91 (0.61 to 1.37)                                    0.91 (0.63 to 1.36)   0.92 (0.31 to 2.30)
  Tic         0.53 (0.29 to 0.89)[\*](#tf4-2){ref-type="table-fn"}   1.75 (0.61 to 3.69)                                     0.76 (0.33 to 1.37)                                    1.49 (0.56 to 2.92)                                     ---                   0.56 (0.24 to 1.00)                                    1.00                                                   1.13 (0.72 to 1.67)                                     1.08 (0.80 to 1.51)                                    1.09 (0.83 to 1.49)   1.08 (0.41 to 2.46)
  Trif        0.41 (0.18 to 0.74)[\*](#tf4-2){ref-type="table-fn"}   1.31 (0.45 to 2.92)                                     0.59 (0.20 to 1.22)                                    1.13 (0.37 to 2.53)                                     ---                   0.42 (0.15 to 0.87)[\*](#tf4-2){ref-type="table-fn"}   0.83 (0.30 to 1.85)                                    1.00                                                    0.99 (0.63 to 1.56)                                    0.99 (0.64 to 1.49)   1.00 (0.35 to 2.39)
  Asp+Clop    1.93 (1.30 to 3.05)[\*](#tf4-2){ref-type="table-fn"}   6.32 (2.86 to 14.22)[\*](#tf4-2){ref-type="table-fn"}   2.71 (1.58 to 4.43)[\*](#tf4-2){ref-type="table-fn"}   5.37 (2.39 to 11.10)[\*](#tf4-2){ref-type="table-fn"}   ---                   2.02 (0.94 to 3.91)                                    3.94 (1.83 to 7.81)[\*](#tf4-2){ref-type="table-fn"}   5.41 (2.33 to 11.28)[\*](#tf4-2){ref-type="table-fn"}   1.00                                                   1.02 (0.75 to 1.37)   1.03 (0.35 to 2.36)
  Asp+Dip     0.87 (0.62 to 1.19)                                    2.86 (1.26 to 6.18)[\*](#tf4-2){ref-type="table-fn"}    1.23 (0.79 to 1.87)                                    2.39 (1.21 to 4.44)[\*](#tf4-2){ref-type="table-fn"}    ---                   0.91 (0.47 to 1.65)                                    1.78 (0.87 to 3.22)                                    2.46 (1.09 to 5.34)[\*](#tf4-2){ref-type="table-fn"}    0.47 (0.27 to 0.76)[\*](#tf4-2){ref-type="table-fn"}   1.00                  1.01 (0.37 to 2.35)
  Asp+Tic     ---                                                    ---                                                     ---                                                    ---                                                     ---                   ---                                                    ---                                                    ---                                                     ---                                                    ---                   1.00

Each cell gives an odds ratio (OR) and 95% credible interval. In the upper diagonal part, the OR compares the column condition with the row condition, and in the lower diagonal part, this OR compares the row condition with the column condition. Asp indicates aspirin; Cilo, cilostazol; Clop, clopidogrel; Dip, dipyridamole; NS, not specified; Sarp, sarpogrelate; Teru, terutroban; Tic, ticlopidine; Trif, triflusal.

Significant results.

[Table 5](#tbl5){ref-type="table"} shows the mean values of SUCRA probabilities that provided the hierarchies for the efficacy and safety of the 11 antiplatelet therapies. In particular, cilostazol displayed the best risk--benefit profile, with SUCRA probabilities of 0.9343, 0.9252, 0.9718, and 0.8850 for reducing stroke recurrence, composite outcome, intracranial hemorrhage, and major bleeding, respectively. [Figures S2](#sd1){ref-type="supplementary-material"} through S5 show the ranking probability of each treatment for outcomes.

###### 

The SUCRA Probabilities of Antiplatelet Therapies on Efficacy and Safety Outcomes

  Treatment                   Stroke Recurrence   Composite Outcome   Intracranial Hemorrhage   Major Bleeding                           
  --------------------------- ------------------- ------------------- ------------------------- ---------------- -------- ----- -------- -----
  Aspirin                     0.3551              7                   0.3465                    8                0.3361   7     0.2136   8
  Cilostazol                  0.9343              1                   0.9252                    1                0.9718   1     0.8850   1
  Clopidogrel                 0.6252              5                   0.5380                    6                0.6487   3     0.4950   5
  Dipyridamole                0.2250              11                  0.2446                    10               ---      ---   0.8221   2
  Sarpogrelate                0.2433              10                  0.2223                    11               0.5538   4     ---      ---
  Terutroban                  0.3547              8                   0.3234                    9                0.2025   8     0.2451   7
  Ticlopidine                 0.6510              3                   0.6854                    2                0.4496   6     0.6740   4
  Triflusal                   0.4551              6                   0.4811                    7                0.6794   2     0.8096   3
  Aspirin plus clopidogrel    0.7033              2                   0.5741                    4                0.1650   9     0.0064   9
  Aspirin plus dipyridamole   0.6321              4                   0.5657                    5                0.4931   5     0.3492   6
  Aspirin plus ticlopidine    0.3208              9                   0.5937                    3                ---      ---   ---      ---

SUCRA indicates surface under the cumulative ranking curve.

Ranking SUCRA probabilities in order as the best treatment, the second best, the third best, and so on, among the antiplatelet therapies.

No inconsistent loop was identified in the analyses of inconsistency factor ([Figure S6](#sd1){ref-type="supplementary-material"}).

Pairwise Meta-Analysis
----------------------

We examined pairwise comparisons of all interventions with available head-to-head data. The results are presented in [Figures 3](#fig03){ref-type="fig"} through [6](#fig06){ref-type="fig"}. In general, the results obtained from pairwise meta-analysis closely matched those of the network meta-analysis. Stroke recurrence, composite efficacy outcome, intracranial hemorrhage, and major bleeding were all significantly reduced by cilostazol versus aspirin. Among the 22 pairwise meta-analyses, each of which included at least 2 trials ([Figures 3](#fig03){ref-type="fig"} through [6](#fig06){ref-type="fig"}), significant heterogeneity was identified in 2 pairwise meta-analyses. One of the 2 pairwise meta-analyses compared ticlopidine with aspirin for preventing stroke recurrence (including 4 trials, I^2^=69.9, *P*=0.019) ([Figure 3](#fig03){ref-type="fig"}), and the other compared ticlopidine with aspirin for composite outcome (including 4 trials, I^2^=73.1, *P*=0.011) ([Figure 4](#fig04){ref-type="fig"}). There was no evidence of heterogeneity across trials in the remaining 20 pairwise meta-analyses.

![Pairwise meta-analyses comparing antiplatelet therapies on the composite outcome. Squares represent point estimates for effect size expressed as an odds ratio, with the size proportional to the inverse variance of the estimate. Diamonds represent pooled estimates. Lines represent 95% CIs. Asp indicates aspirin; CI, confidence interval; Cilo, cilostazol; Clop, clopidogrel; Dip, dipyridamole; OR, odds ratio; Sarp, sarpogrelate; Teru, terutroban; Tic, ticlopidine; Trif, triflusal.](jah30004-e002259-f3){#fig03}

![Pairwise meta-analyses comparing antiplatelet therapies on intracranial hemorrhage. Squares represent point estimates for effect size expressed as an odds ratio, with the size proportional to the inverse variance of the estimate. Diamonds represent pooled estimates. Lines represent 95% CIs. Asp indicates aspirin; CI, confidence interval; Cilo, cilostazol; Clop, clopidogrel; Dip, dipyridamole; OR, odds ratio; Sarp, sarpogrelate; Teru, terutroban; Tic, ticlopidine; Trif, triflusal.](jah30004-e002259-f4){#fig04}

![Pairwise meta-analyses comparing antiplatelet therapies on major bleeding. Squares represent point estimates for effect size expressed as an odds ratio, with the size proportional to the inverse variance of the estimate. Diamonds represent pooled estimates. Lines represent 95% CIs. Asp indicates aspirin; CI, confidence interval; Cilo, cilostazol; Clop, clopidogrel; Dip, dipyridamole; OR, odds ratio; Sarp, sarpogrelate; Teru, terutroban; Tic, ticlopidine; Trif, triflusal.](jah30004-e002259-f5){#fig05}

![Pairwise meta-analyses comparing antiplatelet therapies on stroke recurrence. Squares represent point estimates for effect size expressed as an odds ratio, with the size proportional to the inverse variance of the estimate. Diamonds represent pooled estimates. Lines represent 95% CIs. Asp indicates aspirin; CI, confidence interval; Cilo, cilostazol; Clop, clopidogrel; Dip, dipyridamole; OR, odds ratio; Sarp, sarpogrelate; Teru, terutroban; Tic, ticlopidine; Trif, triflusal.](jah30004-e002259-f6){#fig06}

Sensitivity Analysis
--------------------

The pooled risk estimates did not change substantially in the sensitivity analyses on the primary efficacy outcome from both network meta-analyses and pairwise meta-analyses. [Tables S4](#sd1){ref-type="supplementary-material"} and [S5](#sd1){ref-type="supplementary-material"} and [Figures S7](#sd1){ref-type="supplementary-material"} and [S8](#sd1){ref-type="supplementary-material"} show the full results of the sensitivity analysis.

Discussion
==========

Our network meta-analysis provided evidence-based hierarchies for the efficacy and safety of long-term antiplatelet mono- and dual therapies among patients with ischemic stroke or TIA. It overcame the major limitation of conventional pairwise meta-analyses by combining direct and indirect evidence of relative treatments in the analysis. Results from this study indicated that when compared with antiplatelet monotherapy, dual therapy was not associated with a reduction in stroke recurrence and composite outcome but rather with a significant increase in the risk of major bleeding, especially aspirin plus clopidogrel. In addition, our results showed that cilostazol displayed the best risk--benefit profile among the 11 antiplatelet treatments.

The effects of dual therapy in short- and long-term prevention of recurrent stroke might be different. A recent meta-analysis that combined the results from 14 RCTs reported that dual therapy was more effective than monotherapy in reducing the risk of early recurrent stroke in patients with an index stroke in the previous 3 days.[@b37] The latest AHA/ASA guidelines also recommend that the combination of aspirin and clopidogrel might be considered for initiation within 24 hours of a minor ischemic stroke or TIA.[@b4] For long-term secondary prevention, however, the combination of aspirin and clopidogrel is not recommended by the AHA/ASA guidelines for routine long-term secondary prevention of stroke due to high risk of bleeding,[@b4] which is consistent with our results. Moreover, a recent pairwise meta-analysis based on 7 RCTs that involved 39 574 patients with ischemic stroke or TIA reported that antiplatelet dual therapy lasting \>1 year is not associated with a greater reduction in overall recurrent stroke risk than monotherapy, and that finding also supported our results.[@b29] As far as we know, this network meta-analysis is the first to evaluate the efficacy and safety of long-term antiplatelet therapies after ischemic stroke or TIA and provides the most robust evidence in support of long-term monotherapy as a better choice than long-term dual therapy.

The present study indicated that cilostazol had the best risk--benefit profile among 11 antiplatelet therapies and supported cilostazol as a possible therapeutic option to recommend for secondary prevention of stroke. In the CASISP trial, which included 720 Chinese patients with ischemic stroke within the previous 1 to 6 months, cilostazol reduced the rate of recurrent stroke compared with aspirin (hazard ratio 0.62, 95% CI 0.30 to 1.26), although the benefit was not significant.[@b9] The rate of any hemorrhagic event was also lower in the cilostazol group than in the aspirin group.[@b9] The CSPS 2 study in 2757 Japanese patients is another trial conducted in an East Asian population to compare the efficacy and safety of cilostazol and aspirin in patients with ischemic stroke.[@b11] This trial found that cilostazol significantly reduced the recurrence rate of stroke compared with aspirin (hazard ratio 0.74, 95% CI 0.56 to 0.98) and that major bleeding events occurred in fewer patients on cilostazol than on aspirin (hazard ratio 0.46, 95% CI 0.30 to 0.71).[@b11] On the basis of this evidence, cilostazol has been approved by the China Food and Drug Administration for treatment of noncardioembolic ischemic stroke (license number H10960014), and the latest Chinese guidelines for secondary prevention of stroke recommends cilostazol (100 mg BID) as an alternative to aspirin.[@b53] Similarly, cilostazol is used in Japan for secondary prevention of stroke and is included in the Japanese guidelines for the treatment of ischemic stroke.[@b54] Cilostazol is not licensed in the United States for ischemic stroke or TIA treatment because the efficacy and safety of cilostazol have not been tested in non--East Asian patients. Generalizing the effect of cilostazol to other groups can be challenging because the risk of both ischemic and hemorrhagic stroke is higher in the East Asian population compared with other populations. Further trials in non--East Asian patients are needed to confirm whether cilostazol is effective and safe as a monotherapy for long-term secondary prevention after ischemic stroke or TIA. In addition, cost-effectiveness studies are also required to explore whether long-term use of cilostazol is cost-effective compared with other monotherapies.

Two previous network meta-analyses have been conducted to compare the effect of antiplatelet therapies after ischemic stroke or TIA[@b34],[@b35]; however, neither provided hierarchies for the efficacy and safety of antiplatelet therapies. In one of the studies,[@b34] Thijs et al found that the combination of aspirin and dipyridamole was more effective than aspirin, ticlopidine, and clopidogrel in the prevention of serious vascular events; this finding was not consistent with our analysis. We consider the main reason to be that 13 of the 24 trials identified by Thijs et al did not meet the inclusion criteria for our study because of placebo control or treatment duration \<1 year. In addition, the network meta-analysis by Thijs et al excluded trials assessing triflusal, cilostazol, and sarpogrelate and did not report safety data.[@b34] In the other study,[@b35] Malloy et al reported that more overall hemorrhagic events seemed to occur with the combination of aspirin and clopidogrel than with other treatments, and that finding supported our results. Nevertheless, they found that aspirin plus dipyridamole was more protective than aspirin alone, which was not consistent with our results. Similarly, we consider the main reason to be that 9 of the 24 trials identified by Malloy et al did not meet the inclusion criteria for our study.

The main strength of our study is the inclusion of 24 RCTs with 85 667 patients, thus it is the largest evaluation of long-term antiplatelet therapies for stroke recurrence to date. Furthermore, the network meta-analysis based on a Bayesian model makes indirect comparison among multiple treatments available, especially when there are few trials for direct comparison between different antiplatelet therapies. Consequently, this study can provide evidence-based hierarchies for the long-term efficacy and safety of all available antiplatelet therapies among patients with ischemic stroke or TIA.

This study also has some limitations. First, the full-text articles reviewed were limited to English- and Chinese-language studies, and that can introduce selection bias. A relevant article in French identified from the literature was not included in this study.[@b55] Nonetheless, we believe that the possibility of selection bias is reduced by the relatively large number of studies available in English and Chinese. In addition, previous studies demonstrated that excluding studies published in languages other than English generally has little effect on summary effect estimates.[@b56],[@b57] Second, not all included trials reported the results of intracranial hemorrhage or major bleeding, thus some comparisons between antiplatelet therapies for safety outcomes were not available. Third, all comparisons involving aspirin plus ticlopidine are tenuous, given that only 1 small trial was included in this study, and that may affect the stability of relevant results. Finally, most pairs for comparison included only 1 trial, and cilostazol versus aspirin has not been tested in non--East Asian patients, which might undermine the strength of our results to affect clinical practice.

In conclusion, based on this network meta-analysis, we suggested that long-term monotherapy was a better choice than long-term dual therapy and that cilostazol had the best risk--benefit profile for long-term secondary prevention after stroke or TIA. More high-quality trials in non--East Asian patients are needed to determine whether long-term use of cilostazol is the best option for the prevention of recurrent stroke.
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